Aroa Biosurgery Ltd · ASX:ARX
Aroa Biosurgery — Q4 FY23 Earnings Presentation
13 slides from Aroa Biosurgery's earnings presentation, Apr 27, 2023
Slide 1: Aroa Biosurgery Quarterly Update March 2023
For personal use only AROA BIOSURGERY (ARX) QUARTERLY UPDATE MARCH 2023 Unlocking regenerative healing for everybody
Slide 2: Important Notice and Disclaimer
|2 Important Notice and Disclaimer This presentation (Presentation) is dated 27 April 2023 and has been prepared by Aroa Biosurgery Ltd, New Zealand company number 1980577, ARBN 638 867 473 (AROA or the Company). For personal use only Information in this Presentation The information in this Presenta
Slide 3: Quarterly cash flow
|3 Quarterly cash flow For personal use only Cash receipts from customers of NZ$12.3 million during the quarter. Net cash outflows from operations of NZ$1.9 million for the quarter. Net cash outflows from investing activities was NZ$1.8 million for the quarter, reflecting AROA’s investment into plan
Slide 4: FY23 (preliminary, unaudited)
|4 FY23 (preliminary, unaudited) For personal use only NZ$60.4m1 84%1 Positive Product Revenue vs. Product Gross Margin Normalised EBITDA1 Guidance NZ$60-62m vs. Guidance 84% vs. Guidance ~ breakeven Total revenue ~ NZ$63.1m1 84% ~NZ$45m Cash Balance vs. Guidance ~ NZ$50m 1. Presented on a constant
Slide 5: Highlights
|5 Highlights AROA US Sales: 40 field reps, 166 active Myriad™ accounts1, 4 reps with average run rate over $US1M and 10 reps average run rate of over US$500,000 per annum. For personal use only Myriad - major growth driver: Myriad Matrix™ &, Myriad Morcells™ (FY23 233% YoY constant currency growth)
Slide 6: Step change in soft tissue reconstruction
|6 Step change in soft tissue reconstruction1 For personal use only & Expected to improve healing rates & quality with fewer complications Soft Tissue Soft Tissue Soft Tissue Reconstruction Reconstruction Reconstruction >US$1.4B2 >US$1.0B 3 >US$2.4B4 Plastics, General, Plastics, General, Plastics, G
Slide 7: Enivo Tissue Apposition Platform
|7 Enivo Tissue Apposition Platform For personal use only • Pump and catheter cleared for the removal of surgical and bodily fluids Exudate Vacuum from a closed wound following Reservoir Device Implant plastic surgery and other general Device surgery forming large flaps for hematoma and seroma proph
Slide 8: FY24 Catalysts & Milestones
|8 FY24 Catalysts & Milestones For personal use only AROA Sales TELA AROABioSales Sales Symphony Product Post-COVID Launch Momentum Momentum Momentum COVID-19 expected to have a reduced impact for remainder of FY23 Clinical outcomes & cost savings Well suited to evolving Fully dedicated Fully dedica
Slide 9: Upcoming Investor Events
|9 Upcoming Investor Events For personal use only • Full year results & FY24 guidance Webinar 30th May 2023. • Investor meeting 1st June 2023 1-4:00pm, Sydney Venue (TBC).
Slide 10: Contacts
CONTACTS For personal use only Simon Hinsley Matt Wright Sarah Tora Investor Relations Media Corporate Communications Manager m +61 401 809 653 m +61 451 896 420 m +64 21 531 043 shinsley@aroabio.com matt@nwrcommunications.com.au sarah.tora@aroabio.com Visit our website www.aroabio.com and find us o
Slide 11: AROA at a Glance
| 11 AROA at a Glance Well established high-growth soft tissue regeneration company For personal use only Four product AROA ECM™ platform families for new products, line extensions >US$2.5b2 TAM predominantly sold to US & enables AROA’s tissue apposition platform for existing products hospitals US D
Slide 12: Substantial Growth Opportunities > $2.5B TAM
Substantial Growth Opportunities > $2.5B1 TAM For personal use only Complex Wounds Soft Tissue Reconstruction Total Addressable Market Total Addressable Market > $1.4B2 USD > $1.3B3 USD e.g. Diabetic Foot Ulcers, e.g. Trauma, tumour removal, e.g. Hernia repair, abdominal Venous Ulcers, Pressure Ulce
Slide 13: AROA ECM – Structure & Biology for Regenerative Healing
| 13 AROA ECM – Structure & Biology for Regenerative Healing Unique Extracellular Matrix (ECM) derived from ovine forestomach with proven tissue regeneration properties across multiple products1-6 For personal use only 1. Irvine, S. M., et al. (2011). "Quantification of in vitro and in vivo angiogen